Anti-fungal treatment problems in diabetic patients;Trudności lecznicze grzybicy u chorych na cukrzycȩ

Mikologia Lekarska

Volumn 13, Issue 4, 2006, Pages 315-317

  Hryncewicz Gwozdz, Anita ^a   Plomer Niezgoda, Ewa ^a   Baran, Eugeniusz ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Anti diabetics; Anti fungal agents; Diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; PYRROLE DERIVATIVE; TERBINAFINE;

DIABETES MELLITUS; DRUG ANTAGONISM; DRUG METABOLISM; HUMAN; MYCOSIS; PREVALENCE; REVIEW;

EID: 33845882994     PISSN: 1232986X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Harris M.I., Hadden W.C., Knowler W.C., Bennett P.M.: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes., 1987, 36, 523-534.
2. Harris M.I.: Epidemiology of diabetes mellitus among the elderly in the United States. Clin. Geriatr. Med., 1990, 6, 703-719.
3. Geerlings S.E., Hoepelman A.I.: Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol. Med. Microbiol., 1999, 26, 259-265.
4. Bhadada S., Bhansali A., Reddy K.S., Bhat R.V., Khandelwal N., Gupta A.K.: Rhinoorbital-cerebral mucormycosis in type 1 diabetes mellitus. Indian. J. Pediatr., 2005, 72, 671-674.
5. Odds F.C., Evans E.G., Taylor M.A., Wales J.K.: Prevalence of pathogenic yeasts and humoral antibodies to Candida in diabetic patients. J. Clin. Pathol., 1978, 31, 840-844.
6. Knight L., Fletcher J.: Growth of Candida albicans in saliva: stimulation by glucose associated with antibiotics, corticosteroids, and diabetes mellitus. J. Infect. Dis., 1971, 123, 371-377.
7. Aly F.Z., Blackwell C.C., Mackenzie D.A., Weir D.M., Clarke B.F.: Factors influencing oral carriage of yeasts among individuals with diabetes mellitus. Epidemiol. Infect., 1992, 109, 507-518.
8. Bai K.Y., Reddy C.D., Abu-Talib S. H.: Oral candidal carriage in young insulin dependent diabetics. J. Indian. Soc. Pedod. Prev. Dent., 1995, 13, 20-23.
9. Manfredi M., McCullough M.J., Al-Karaawi Z.M., Hurel S.J., Porter S.R.: The isolation, identification and molecular analysis of Candida spp. isolated from the oral cavities of patients with diabetes mellitus. Oral. Microbiol. Immunol., 2002, 17, 181-185.
10. Fisher B.M., Lamey P.J., Samaranayake L.P., MacFarlane T.W., Frier B.M.: Carriage of Candida species in the oral cavity in diabetic patients: relationship to glycaemic control. J. Oral. Pathol., 1987, 16, 282-284.
11. Dorocka-Bobkowska B., Budtz-Jorgensen E., Wloch S.: Non-insulin- dependent diabetes mellitus as a risk factor for denture stomatitis. J. Oral. Pathol. Med., 1996, 25, 411-415.
12. Gupta A.K., Konnikov N., McDonald P.I., Rich P., Rodger N.W., Edmonds M.: Prevalence and epidemiology of tonail onychomycosis in diabetic subjects: a multicentre study. Br. J. Dermatol., 1998, 138, 665-671.
13. Manfredi M., McCullough M.J., Polonelli L., Conti S., Al-Karaawi Z.M., Vescovi P., Porter S.R.: In vitro antifungal susceptibility to six antifungal agents of 229 Candida isolates from patients with diabetes mellitus. Oral. Microbiol. Immunol., 2006, 21, 177-182.
14. Delescluse J., Cauwenbergh G., Degreef H.: Itraconazole, a new orally active antifungal, in the treatment of pityriasis versicolor. Br. J. Dermatol., 1986, 114, 701-703.
15. Papini M., Kalandra P.: L'itraconazolo nella profilassi e nel trattamento delle dermatomicosi. Micol. Dermatoz., 1989, 3, 45-49.
16. Denning D.W., Lee J.Y., Hostetler J.S., Pappas P., Kauffman C.A., Dewsnup D.H., Galgiani J.N., Graybill J.R., Sugar A.M., Catanzaro.: NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am. J. Med., 1994, 97, 135-144.
17. Gonzalez O.M., Martinez A.E.: Itraconazole in treatment of Candida vulvovaginitis in patients with type II diabetes mellitus (non-insulin dependent). Ginecol. Obstet. Mex., 1995, 63, 15-18.
18. Gupta A., Gover M., Lynde C.: Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. J. Eur. Acad., Dermatol. Venereol., 2006, 20, 1188-1193.
19. Arredondo G., Suarez E., Calvo R., Vazquez J.A., Garcia-Sanchez J., Martinez-Jorda R.: Serum protein binding of itraconazole and fluconazole in patients with diabetes mellitus. J. Antimicrob. Chemother., 1999, 43, 305-307.
20. Venkatakrishnan K., von Moltke L.L., Greenblatt D.J.: Effects of the antifungal agents on oxidative drug metabolism: clinicalrelevance. Clin. Pharmacokinet., 2000, 38, 111-180.
21. Verspeelt J., Marynissen G., Gupta A.K., De Doncker P.: Safety of itraconazole in diabetic patients. Dermatology, 1999, 198, 382-384.
22. Albreski D.A., Gross E.G.: The safety of itraconazole in the diabetic papulation. J. Am. Pediatr. Med. Assoc., 1999, t. 89, 339-345.